当前位置:Ajesci > 期刊 > 一种口服的重组幽门螺杆菌疫苗在中国儿童中的

期刊

一种口服的重组幽门螺杆菌疫苗在中国儿童中的

Evidence builds for benefits of exercise in pediatric MS

发布者:安吉尔 发布时间:2015-11-07
  作者:Zeng, M., Mao, X.-H., Li, J.-X., Tong, W.-D., Wang, B., Zhang, Y.-J., Guo, G., Zhao, Z.-J., Li, L., Wu, D.-L., Lu, D.-S., Tan, Z.-M., Liang, H.-Y., Wu, C., Li, D.-H., Luo, P., Zeng, H., Zhang, W.-J., Zhang, J.-Y., Guo, B.-T., Zhu, F.-C. , Zou, Q.-M.
 
  机构: 江苏省疾病预防控制中心
 
  期刊: 《Lancet》2015年10月10002期366卷
  Background Helicobacter pylori is one of the most common gastric pathogens, affecting at least half the world's population, and is strongly associated with gastritis, peptic ulcer, gastric adenocarcinoma, and lymphoma. We aimed to assess the efficacy, safety, and immunogenicity of a three-dose oral recombinant H pylori vaccine in children in China. Methods We did this randomised, double-blind, placebo-controlled, phase 3 trial at one centre in Ganyu County, Jiangsu Province, China. Healthy children aged 6-15 years without past or present H pylori infection were randomly assigned (1:1), via computer-generated randomisation codes in blocks of ten, to receive the H pylori vaccine or placebo. Participants, their guardians, and study investigators were masked to treatment allocation. The primary efficacy endpoint was the occurrence of H pylori infection within 1 year after vaccination. We did analysis in the per-protocol population. This trial is registered with ClinicalTrials.gov, number NCT02302170. Findings Between Dec 2, 2004, and March 19, 2005, we randomly assigned 4464 participants to either the vaccine group (n=2232) or the placebo group (n=2232), of whom 4403 (99%) participants completed the three-dose vaccination schedule and were included in the per-protocol efficacy analysis. We extended follow-up to 3 years. We recorded 64 events of H pylori infection within the first year (14 events in 2074·3 person-years at risk in the vaccine group vs 50 events in 2089·6 person-years at risk in the placebo group), resulting in a vaccine efficacy of 71·8% (95% CI 48·2-85·6). 157 (7%) participants in the vaccine group and 161 (7%) participants in the placebo group reported at least one adverse reaction. Serious adverse events were reported in five (<1%) participants in the vaccine group and seven (<1%) participants in the placebo group, but none was considered to be vaccination related. Interpretation The oral recombinant H pylori vaccine was effective, safe, and immunogenic in H pylori-naive children. This vaccine could substantially reduce the incidence of H pylori infection; however, follow up over a longer period is needed to confirm the protection of the vaccine against H pylori-associated diseases. ? 2015 Elsevier Ltd.

Ajesci版权所有 未经授权请勿转载!

来源: 安吉尔
安吉尔:AJESCI生物医学 为生物医学工作者及各类科研单位提供医学sci服务流程全透明、安全保密有保障 实时汇报项目动态 终搞投稿 均有 你确认拍板 千里之外也尽在掌握 技术领先、服务完善的多元化平台,主要提供医学专业 协助SCI论文服务、发表、SCI写作指导、论文翻译、母语润色、检测查重、协助论文发表、论文写作指导、课题设计咨询、数据统计服务等全方位服务,感谢您浏览我们的网站,能为您服务是我们的荣幸! 马上访问安吉尔网站http://www.ajesci.com/

当前最热

 热门病例 more

 热门指南  more

医生社区